GALMED PHARMACEUTICALS LTD - SHS (GLMD)

CUSIP: M47238106

Q2 2020 13F Holders as of 30 Jun 2020

Share change
+360,753
SEC-reported price per share
$4.78
Number of holders
24
Value change
+$2,993,480
Number of buys
11
Number of sells
10

Security key

M47238106

Report period

Q2 2020

Institutions

24

Top holders

10

Ownership snapshot

Top reported holders of GLMD - GALMED PHARMACEUTICALS LTD - SHS (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
BVF INC/IL
Disclosed value leader
BVF INC/IL
Comparable rows
0/15
Latest evidence
31 Mar 2020
13F Highest disclosed value: $6,340,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

BVF INC/IL has the largest disclosed position value at $6.34M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens BVF INC/IL's linked filing trail.
Disclosed position value Top 5
BVF INC/IL $6.34M
Nantahala Capital Management, LLC $4.51M
IBEX INVESTORS LLC $3.34M
Vivo Capital, LLC $2.98M
683 Capital Management, LLC $2.71M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
BVF INC/IL
13F
Company
13F
—
denominator unverified
$6,340,000
1,832,484 shares
— 31 Mar 2020
Nantahala Capital Management, LLC
13F
Company
13F
—
denominator unverified
$4,511,000
1,303,652 shares
— 31 Mar 2020
IBEX INVESTORS LLC
13F
Company
13F
—
denominator unverified
$3,339,000
965,000 shares
— 31 Mar 2020
Vivo Capital, LLC
13F
Company
13F
—
denominator unverified
$2,976,000
860,103 shares
— 31 Mar 2020
683 Capital Management, LLC
13F
Company
13F
—
denominator unverified
$2,706,000
781,820 shares
— 31 Mar 2020
RAYMOND JAMES & ASSOCIATES
13F
Company
13F
—
denominator unverified
$1,191,000
344,195 shares
— 31 Mar 2020
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2020

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
24
Shares
7,419,865
Rows available
24
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2020 vs Q1 2020 Across Filers

Q1 2020 holders
31
Q2 2020 holders
24
Holder diff
-7
Investor Q1 2020 Shares Q2 2020 Shares Share Diff Share Chg % Q1 2020 value Q2 2020 value Value change Value Chg %
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .